Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010:78:43-86.
doi: 10.1016/B978-0-12-385032-4.00002-1.

Adaptive immunity to the hepatitis C virus

Christopher M Walker  1
Affiliations
Review

Adaptive immunity to the hepatitis C virus

Christopher M Walker. Adv Virus Res. 2010.

Abstract

The hepatitis C virus (HCV) is a global public health problem affecting approximately 2% of the human population. The majority of HCV infections (more than 70%) result in life-long persistence of the virus that substantially increases the risk of serious liver diseases, including cirrhosis and hepatocellular carcinoma. The remainder (less than 30%) resolves spontaneously, often resulting in long-lived protection from persistence upon reexposure to the virus. To persist, the virus must replicate and this requires effective evasion of adaptive immune responses. In this review, the role of humoral and cellular immunity in preventing HCV persistence, and the mechanisms used by the virus to subvert protective host responses, are considered.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Three patterns of viremia have been described during the acute phase of HCV infection. In individuals who clear the infection (left panel), viremia peaks several weeks after infection when functional polyclonal CD4+ and CD8+ T responses targeting epitopes in most viral cell proteins are first detected in blood. CD8+ T cells lose expression of the coinhibitory molecule PD-1 and gain expression of the CD127 IL-7 receptor that is required for self-renewal of memory populations. Transient control of viremia can be observed for several months to a year after infection (middle panel). As indicated in the panel, these infections frequently persist, but resolution has also been observed after a prolonged period of low-level, fluctuating viremia. The end of transient virus control is associated with loss of CD4+ T helper cell function. Infections that persist without transient control of viremia have been described (right panel). T cell responses, if detected, are not sustained and usually target a limited number of epitopes. Most CD8+ T cells express high levels of PD-1. CD127 is low or absent. This exhausted phenotypic profile may be attenuated if the targeted viral epitope acquires an escape mutation (see Section IV, C1 and C2 for details).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abe K, Inchauspe G, Shikata T, Prince AM. Three different patterns of hepatitis C virus infection in chimpanzees. Hepatology. 1992;15:690. - PubMed
    1. Abel M, Sene D, Pol S, Bourliere M, Poynard T, Charlotte F, Cacoub P, Caillat-Zucman S. Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection. Hepatology. 2006;44:1607. - PubMed
    1. Aberle JH, Formann E, Steindl-Munda P, Weseslindtner L, Gurguta C, Perstinger G, Grilnberger E, Laferl H, Dienes HP, Popow-Kraupp T, Ferenci P, Holzmann H. Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection. J Clin Virol. 2006;36:24. - PubMed
    1. Accapezzato D, Francavilla V, Paroli M, Casciaro M, Chircu LV, Cividini A, Abrignani S, Mondelli MU, Barnaba V. Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest. 2004;113:963. - PMC - PubMed
    1. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA. 1999;96:12766. - PMC - PubMed